Tom 15, Nr 2 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-07-12
Wyświetlenia strony
1520
Wyświetlenia/pobrania artykułu
5417
Postępowanie w chorobie von Willebranda. Zalecenia Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów 2022
Journal of Transfusion Medicine 2022;15(2):100-126.
Streszczenie
Niniejsze wytyczne, przygotowane przez Grupę do spraw Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów, stanowią aktualizację wytycznych wydanych w 2008 roku [1]. Wobec braku odpowiednio zaprojektowanych badań klinicznych z randomizacją, dotyczących diagnostyki i leczenia choroby von Willebranda, przedstawione zalecenia opierają się w dużej mierze na badaniach retrospektywnych, opiniach ekspertów, opisach serii przypadków, jak też na wytycznych opublikowanych w innych krajach. W indywidualnych sytuacjach klinicznych decydujące znaczenie mogą mieć ocena kliniczna oraz doświadczenie lekarza.
Słowa kluczowe: choroba von Willebrandaczynnik von Willebrandaskazy krwotocznewytyczne
Referencje
- Zdziarska J, Chojnowski K, Klukowska A, et al. Postępowanie w chorobie von Willebranda. Zalecenia Polskiego Towarzystwa Hematologów i Transfuzjologów 2008. Medycyna Praktyczna, wyd specjalne 12/2008.
- National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI). The diagnosis, evaluation, and management of von Willebrand disease. Bethesda (MD): U.S. Department of Health and Human Services. ; 2007.
- Connell NT, James PD, Brignardello-Petersen R, et al. von Willebrand disease: proposing definitions for future research. Blood Adv. 2021; 5(2): 565–569.
- Keesler DA, Flood VH. Current issues in diagnosis and treatment of von Willebrand disease. Res Pract Thromb Haemost. 2018; 2(1): 34–41.
- Colonne CK, Reardon B, Curnow J, et al. Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? A Focus on Clinical Considerations and Recommendations. J Blood Med. 2021; 12: 755–768.
- Sharma R, Flood VH, Sharma R, et al. Advances in the diagnosis and treatment of Von Willebrand disease. Blood. 2017; 130(22): 2386–2391.
- James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 5(1): 280–300.
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021; 5(1): 301–325.
- Othman M, Gresele P, Othman M, et al. Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH. J Thromb Haemost. 2020; 18(8): 1855–1858.
- Seidizadeh O, Peyvandi F, Mannucci PM. Von Willebrand disease type 2N: An update. J Thromb Haemost. 2021; 19(4): 909–916.
- Casonato A, Pontara E, Sartorello F, et al. Identifying type Vicenza von Willebrand disease. J Lab Clin Med. 2006; 147(2): 96–102.
- Leebeek FWG, Atiq F. How I manage severe von Willebrand disease. Br J Haematol. 2019; 187(4): 418–430.
- James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013; 122(5): 636–640.
- Franchini M, Mannucci PM. Alloantibodies in von Willebrand Disease. Semin Thromb Hemost. 2018; 44(6): 590–594.
- Scott M, Hay CRM, Elkhalifa S, et al. Management of pregnancy in type 3 von Willebrand disease with alloantibodies. Br J Haematol. 2018; 182(3): 440–442.
- Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020; 105(8): 2032–2037.
- Becq A, Rahmi G, Perrod G, et al. Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management. Gastrointest Endosc. 2017; 86(5): 792–806.
- Franchini M, Mannucci P. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thrombo Haemost. 2017; 112(09): 427–431.
- James AH, Eikenboom J, Federici AB. State of the art: von Willebrand disease. Haemophilia. 2016; 22 Suppl 5: 54–59.
- Favaloro EJ. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making. Thromb Res. 2020; 188: 17–24.
- Castaman G, Goodeve A, Eikenboom J, et al. European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013; 98(5): 667–674.
- Baronciani L, Peyvandi F. How we make an accurate diagnosis of von Willebrand disease. Thromb Res. 2020; 196: 579–589.
- Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014; 167(4): 453–465.
- Lavin M, Aguila S, Schneppenheim S, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017; 130(21): 2344–2353.
- Boender J, Kruip MJ, Leebeek FWG. A diagnostic approach to mild bleeding disorders. J Thromb Haemost. 2016; 14(8): 1507–1516.
- Rydz N, Grabell J, Lillicrap D, et al. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia. 2015; 21(5): 636–641.
- Atiq F, Meijer K, Eikenboom J, et al. WiN study group. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol. 2018; 182(1): 93–105.
- Sanders YV, Giezenaar MA, Laros-van Gorkom BAP, et al. WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014; 12(7): 1066–1075.
- Favaloro EJ. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease. Am J Hematol. 2017; 92(1): 114–118.
- Bodó I, Eikenboom J, Montgomery R, et al. von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015; 13(7): 1345–1350.
- Flood VH, Gill JC, Christopherson PA, et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost. 2012; 10(7): 1425–1432.
- Mezzano D, Quiroga T. Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research. J Thromb Haemost. 2019; 17(2): 257–270.
- Szederjesi A, Baronciani L, Budde U, et al. Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers. J Thromb Haemost. 2020; 18(10): 2513–2523.
- Favaloro EJ. Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data. Blood Adv. 2022; 6(2): 416–419.
- Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013; 122(23): 3735–3740.
- Swami A, Kaur V. von Willebrand Disease: A Concise Review and Update for the Practicing Physician. Clin Appl Thromb Hemost. 2017; 23(8): 900–910.
- Kruse-Jarres R, Johnsen J. How I treat type 2B von Willebrand disease. Blood. 2018; 131(12): 1292–1300.
- Miesbach W. Perioperative management for patients with von Willebrand disease: Defining the optimal approach. Eur J Haematol. 2020; 105(4): 365–377.
- Kasper CK. Hemophilia of Georgia, U.S.A. Protocols for the treatment of haemophilia and von Willebrand disease. Haemophilia. 2000; 6 Suppl 1: 84–93.
- Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood. 2015; 125(6): 907–914.
- Peyvandi F, Kouides P, Turecek PL, et al. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Rev. 2019; 38: 100572.
- Peng HT. Hemostatic agents for prehospital hemorrhage control: a narrative review. Mil Med Res. 2020; 7(1): 13.
- Martinowitz U, Schulman S, Horoszowski H, et al. Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Clin Orthop Relat Res. 1996(328): 65–75.
- Rodriguez-Merchan E. Fibrin glue for local haemostasis in haemophilia surgery. Hospital Practice. 2017; 45(5): 187–191.
- Chiara O, Cimbanassi S, Bellanova G, et al. A systematic review on the use of topical hemostats in trauma and emergency surgery. BMC Surg. 2018; 18(1): 68.
- Sanders YV, de Wee EM, Meijer K, et al. WiN Study Group. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost. 2013; 11(5): 845–854.
- Seaman CD, Yabes J, Comer DM, et al. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost. 2015; 13(11): 1999–2003.
- Hassan SA, Amer S, Qureshi W, et al. Treating symptomatic coronary artery disease in patients with Von Willebrand disease. Hematol Oncol Stem Cell Ther. 2013; 6(3-4): 101–104.
- Fogarty PF, Blair A, Vega R, et al. Interventional therapies and in-hospital outcomes in acute coronary syndromes complicated by von Willebrand disease. Haemophilia. 2017; 23(3): 400–407.
- Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood. 2016; 128(2): 178–184.
- Yaish H. Inhibitors to Von Willebrand Factor in Type 3 Von Willebrand Disease (VWD). Biomed J Sci & Tech Res . 2017; 1(3): 552–555.
- Faganel Kotnik B, Strandberg K, Debeljak M, et al. von Willebrand factor alloantibodies in type 3 von Willebrand disease. Blood Coagul Fibrinolysis. 2020; 31(1): 77–79.
- Nummi V, Lehtinen E, Mäkipernaa A, et al. Intravenous immunoglobulin treatment in a type 3 von Willebrand disease patient with alloantibodies and a life-threatening gastrointestinal bleed. Haemophilia. 2019; 25(4): e291–e293.
- Pergantou H, Xafaki P, Adamtziki E, et al. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia. 2012; 18(3): e66–e67.
- Charlebois J, Rivard GÉ, St-Louis J. Management of acquired von Willebrand syndrome. Transfus Apher Sci. 2018; 57(6): 721–723.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6: 1–158.
- Harrison P, Mackie I, Mumford A, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol . 2011; 155(1): 30–44.
- Israels SJ. Laboratory testing for platelet function disorders. Int J Lab Hematol. 2015; 37 Suppl 1: 18–24.
- Gosselin RC, Marlar RA. Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results. Semin Thromb Hemost. 2019; 45(5): 433–448.
